ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 176 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2016. The put-call ratio across all filers is 0.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $5,084,000 | -34.8% | 75,000 | -32.3% | 0.74% | -29.7% |
| Q4 2016 | $7,793,000 | -0.9% | 110,842 | 0.0% | 1.05% | +21.1% |
| Q3 2016 | $7,863,000 | +45.0% | 110,842 | 0.0% | 0.87% | +12.7% |
| Q2 2016 | $5,421,000 | -21.8% | 110,842 | +1.2% | 0.77% | -26.3% |
| Q1 2016 | $6,932,000 | -43.6% | 109,500 | 0.0% | 1.04% | -29.0% |
| Q4 2015 | $12,284,000 | +16.5% | 109,500 | 0.0% | 1.47% | -12.7% |
| Q3 2015 | $10,546,000 | +1.0% | 109,500 | +7.4% | 1.68% | +21.2% |
| Q2 2015 | $10,444,000 | +64.9% | 102,000 | 0.0% | 1.39% | +41.9% |
| Q1 2015 | $6,333,000 | +20.3% | 102,000 | -15.0% | 0.98% | +20.6% |
| Q4 2014 | $5,266,000 | -22.5% | 120,000 | 0.0% | 0.81% | -41.9% |
| Q3 2014 | $6,792,000 | +26.1% | 120,000 | 0.0% | 1.40% | -2.1% |
| Q2 2014 | $5,387,000 | +83.7% | 120,000 | +100.0% | 1.43% | +111.7% |
| Q1 2014 | $2,933,000 | – | 60,000 | – | 0.67% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 437,512 | $31,772,000 | 2.80% |
| RTW INVESTMENTS, LP | 1,373,284 | $99,728,000 | 2.06% |
| Rock Springs Capital Management LP | 1,028,109 | $74,661,000 | 1.88% |
| Privium Fund Management B.V. | 112,727 | $8,186,000 | 1.81% |
| Avidity Partners Management LP | 869,000 | $63,107,000 | 1.31% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 525,100 | $38,133,000 | 1.16% |
| Boxer Capital, LLC | 200,000 | $14,524,000 | 0.75% |
| SECTOR GAMMA AS | 46,221 | $3,357,000 | 0.73% |
| FEDERATED HERMES, INC. | 3,987,728 | $289,589,000 | 0.65% |
| EMERALD ADVISERS, LLC | 223,952 | $16,263,000 | 0.62% |